Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Soo In Kim is active.

Publication


Featured researches published by Soo In Kim.


Virology | 2008

A hantavirus causing hemorrhagic fever with renal syndrome requires gC1qR/p32 for efficient cell binding and infection.

Yun Choi; Young Chan Kwon; Soo In Kim; Jung Min Park; Kyung Hee Lee; Byung Yoon Ahn

Hantaan virus (HTNV) is a pathogenic hantavirus that causes hemorrhagic fever with renal syndrome (HFRS). HTNV infection is mediated by alpha v beta3 integrin. We used protein blots of Vero E6 cell homogenates to demonstrate that radiolabeled HTNV virions bind to gC1qR/p32, the acidic 32-kDa protein known as the receptor for the globular head domain of complement C1q. RNAi-mediated suppression of gC1qR/p32 markedly reduced HTNV binding and infection in human lung epithelial A549 cells. Conversely, transient expression of either simian or human gC1qR/p32 rendered non-permissive CHO cells susceptible to HTNV infection. These results suggest an important role for gC1qR/p32 in HTNV infection and pathogenesis.


RNA | 2009

Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus

Duckhyang Shin; Hyeon Lee; Soo In Kim; Yeup Yoon; Meehyein Kim

RNA interference (RNAi)-based gene silencing possesses great therapeutic potential for inhibiting replication of human viruses such as hepatitis C virus (HCV). However, one of the putative limitations for its use as a therapy is the rapid emergence of escape variants. These contain deletions or mutations within the viral genome sequences complementary to the small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) being used for treatment. As a potential solution to this problem, we constructed an expression system for duplex RNAs harboring two siRNA units using convergent H1 and U6 Pol III promoters. Here, the length and orientation of the transcript, tandem siRNA (tsiRNA), were optimized to be processed by the intracellular ribonuclease Dicer into functional siRNAs targeting different sequences. Assessment in transfected cells indicates that the length of the tsiRNA duplex (40-42 base pairs) is more critical for both siRNA-producing capacity and gene silencing activity than the orientation of each siRNA unit. In Huh7 cells replicating full-length HCV RNA, expression of length-optimized tsiRNA inhibited viral protein levels as efficiently as a single 21-nucleotide siRNA-expression construct, without affecting miRNA maturation or induction of an interferon response. We verified that the anti-viral activity of tsiRNA was achieved by precise cleavage of two target sites. A distinct advantage of this strategy is that each side of the optimized linear duplex RNA could enter into the Dicer-mediated processing machinery, thus likely providing more equal and efficient production of multiple siRNAs required for reducing the chance of viral escape.


Biochemical and Biophysical Research Communications | 2009

Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice.

Hyeon Woo Lee; Soo In Kim; Duckhyang Shin; Yeup Yoon; Tae Hyun Choi; Gi Jeong Cheon; Meehyein Kim

Apolipoprotein A-I (apo A-I), the major protein component of high density lipoprotein (HDL), plays a key role in reverse cholesterol transport from peripheral tissues to liver or steroidogenic organs. Class B, type 1 scavenger receptor (SR-BI) is abundantly expressed in these target tissues and recognizes apo A-I of HDL for selective cholesteryl ester uptake. Recently, we reported the liver-targeting potential of plasma-derived apo A-I and the efficient delivery of therapeutic small interfering RNAs (siRNA) assembled with cationic liposome and apo A-I. In this study, we expressed and purified recombinant human apo A-I (rhapo A-I), low endotoxin grade, from an Escherichia coli expression system. The liver-targeting property of rhapo A-I was compared to that of plasma-derived apo A-I. Using a hepatitis C virus mouse model, intravenous administration of virus-specific siRNA with liposome and rhapo A-I significantly inhibited viral protein expression, demonstrating great promise for its use in clinical applications.


Journal of Hepatology | 2009

Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes.

Soo In Kim; Duckhyang Shin; Hyeon Lee; Byung-Yoon Ahn; Yeup Yoon; Meehyein Kim


Archive | 2010

Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs

Meehyein Kim; Soo In Kim; Duckhyang Shin; Mahnhoon Park


Archive | 2006

Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same

Meehyein Kim; Duckhyang Shin; Soo In Kim; Mahnhoon Park


Archive | 2008

METHOD FOR ENHANCING SERUM STABILITY AND LOWERING IMMUNE RESPONSE OF SIRNA DOWN-REGULATING GENE EXPRESSION OF HBV OR HCV

Soo In Kim; Duckhyang Shin; Hyeon Woo Lee; Meehyein Kim; Doo-Hong Park; Yeup Yoon


Archive | 2008

Linear double-stranded rna molecule interfering with different target genes

Meehyein Kim; Duckhyang Shin; Hyeon Woo Lee; Soo In Kim; Yeup Yoon


Virology | 2009

Erratum to “A hantavirus causing hemorrhagic fever with renal syndrome requires gC1qR/p32 for efficient cell binding and infection” [Virology 381 (2008) 178–183]

Yun Choi; Young Chan Kwon; Soo In Kim; Jung Min Park; Kyung Hee Lee; Byung Yoon Ahn


Archive | 2006

Small interfering rna specific for hcv and therapeutic agent for hepatitis c comprising the same

Meehyein Kim; Duckhyang Shin; Mahnhoon Park; Soo In Kim

Collaboration


Dive into the Soo In Kim's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gi Jeong Cheon

Seoul National University Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hyeon Lee

Biotechnology Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge